drugset / Trial / NCT05337657
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
GB491-005 is a multicenter, open-label, phase Ib Clinical Trial study to evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GB491 in combination with Letrozole in Previously Untreated Patients with HR-positive, HER2-negative Advanced Breast Cancer
Timeline
- Start
- 2021-06-02
- Primary completion
- 2023-12-12
- Completion
- 2024-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GB491 | Unknown | 150 mg | — |
| Subject | Letrozole | Other / unclassified | — | — |